|
Video: What is a Stock Split?
|
|
Windtree Therapeutics is a biopharmaceutical company focused on the development of therapeutics. Co.'s primary product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure. Co.'s heart failure cardiovascular portfolio also includes sarco endoplasmic reticulum Ca2+ -ATPase 2a (SERCA2a) activators. This research program is evaluating these preclinical product candidates, including oral and intravenous SERCA2a activator heart failure compounds. In addition, Co.'s cardiovascular drug product candidates include rostafuroxin, a product candidate for the treatment of hypertension in patients with a specific genetic profile. According to our WINT split history records, Windtree Therapeutics has had 1 split. | |
|
Windtree Therapeutics (WINT) has 1 split in our WINT split history database. The split for WINT took place on February 24, 2023. This was a 1 for 50 reverse split, meaning for each 50 shares of WINT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 20 share position following the split.
When a company such as Windtree Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the WINT split history from start to finish, an original position size of 1000 shares would have turned into 20 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Windtree Therapeutics shares, starting with a $10,000 purchase of WINT, presented on a split-history-adjusted basis factoring in the complete WINT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/31/2014 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$107.50 |
|
End price/share: |
$0.37 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.66% |
|
Average Annual Total Return: |
-43.30% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$34.40 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
02/24/2023 | 1 for 50 |
|
|